Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences ended Q1 with $311.3 million in cash, sufficient to fund operations into the first half of 2028, while advancing its pipeline of autoimmune therapies. The company expects to initiate a Phase 2 trial for JADE101 in IgA nephropathy in Q2 2026, with interim data expected in 2027, and start a Phase 1 trial for JADE201 in rheumatoid arthritis this quarter. Executive leadership was strengthened with the appointment of Dr. Edward R.
Key figures
- Drug Name
- JADE101
- Guidance
- Cash runway into first half of 2028; Phase 2 trial of JADE101 expected to begin in Q2 2026; Phase 1 trial of JADE201 expected to begin in Q2 2026
- Phase Of Trial
- Phase 2
- Net loss
- 40400000
- Ga expenses
- 7400000
- Rd expenses
- 36100000
- Cash position
- 311300000
- Shares outstanding
- 70745453
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.